BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com).

If you have any questions on BMJ Open’s open peer review process please email info.bmjopen@bmj.com
Development and internal validation of the Edmonton Obesity Staging System-2 Risk Tool (EOSS-2 Risk Tool)

| Journal: | BMJ Open |
|----------|----------|
| Manuscript ID | bmjopen-2022-061251 |
| Article Type: | Original research |
| Date Submitted by the Author: | 19-Jan-2022 |
| Complete List of Authors: | Atlantis, Evan; Western Sydney University; The University of Sydney John, James Rufus; Western Sydney University Hocking, SL; University of Sydney, Charles Perkins Centre Peters, Kath; Western Sydney University Williams, Kathryn; The University of Sydney Dugdale, Paul; ANU, College of Medicine Biology and Environment Fahey, P; Western Sydney, School of Science and Health |
| Keywords: | GENERAL MEDICINE (see Internal Medicine), Diabetes & endocrinology < INTERNAL MEDICINE, PRIMARY CARE, PREVENTIVE MEDICINE |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Development and internal validation of the Edmonton Obesity Staging System-2 Risk Tool (EOSS-2 Risk Tool)

Evan Atlantis¹,²*; James Rufus John¹; Samantha Hocking³,⁴; Kath Peters¹; Kathryn Williams⁵,⁶; Paul Dugdale⁷; Paul Fahey¹

¹School of Health Sciences, Western Sydney University, Penrith, New South Wales, Australia
²Discipline of Medicine, Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Nepean, New South Wales, Australia
³The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia;
⁴Metabolism & Obesity Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
⁵Charles Perkins Centre – Nepean, The University of Sydney, New South Wales, Australia
⁶Nepean Blue Mountains Family Metabolic Heath Service, The Nepean Blue Mountains Local Health District, Nepean, New South Wales, Australia
⁷College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia

*Corresponding author:

Name: Evan Atlantis¹,²

Email: E.Atlantis@westernsydney.edu.au

Short running title Development and internal validation of the EOSS-2 Risk Tool.

Keywords Weight Related Complications; Diagnostic Techniques and Procedures; Mass Screening; Overweight
Abstract

Objective

Excess weight and related health complications remain under diagnosed and poorly treated in general practice. We aimed to develop and validate a brief screening tool for determining the presence of unknown clinically significant weight related health complications for potential application in general practice.

Design

We considered 14 self-reported candidate predictors of clinically significant weight related health complications according to the Edmonton Obesity Staging System (EOSS score of $\geq 2$) and developed models using multivariate logistic regression across training and test data sets. The final model was chosen based on the Area under the Receiver Operating Characteristic (AROC) curve and the Hosmer–Lemeshow (HL) statistic; and validated using sensitivity, specificity, and Positive Predictive Value (PPV).

Setting and participants

We analysed cross-sectional data from the Australian Health Survey (AHS) 2011-13 sample aged between 18 and 65 years ($n=7,518$) with at least overweight or obesity.

Results

An EOSS $\geq 2$ classification was present in 78% of the sample. Of 14 candidate risk factors, six (family history of diabetes, hypertension, high sugar in blood/urine, high cholesterol, and self-reported bodily pain and disability) were automatically included based on definitional or obvious correlational criteria. Three variables were retained in the final multivariate model (age, self-assessed health, and history of depression/anxiety). The risk tool correctly identified those at ‘extremely high risk’ (PPV of 89%) and ‘very high risk’ (PPV of 67%) of having EOSS $\geq 2$. Almost 42% of those at ‘high risk’ (<7 points) met EOSS $\geq 2$ criteria.

Conclusion
The EOSS-2 Risk Tool is a simple, safe, and accurate screening tool for diagnostic criteria for clinically significant weight related complications for potential application in general practice. Research to determine the feasibility and applicability of the EOSS-2 Risk Tool for improving weight management approaches in general practice is warranted.

**Strengths and limitations of this study**

- The EOSS-2 Risk Tool was developed and validated in an Australian sample of community-based ‘high risk’ individuals for potential application in general practice.
- The EOSS-2 Risk Tool efficiently detects the presence of unknown clinically significant weight related complications according to the widely used Edmonton Obesity Staging System.
- Research to determine the feasibility and applicability of the EOSS-2 Risk Tool for improving weight management approaches in specific general practice settings is warranted.

**Introduction**

Overweight and obesity is a major public health issue challenging global health systems.\(^1\) It affects a quarter of all young people (aged 2-17 years) and two-thirds of all adults in Australia.\(^2\) We recently estimated that millions of Australians have weight related health complications (complex and/or chronic conditions) associated with increased avoidable health service use and hospitalizations.\(^3\) The most common weight related health problems include cancer, stroke, heart disease, kidney disease, dementia, diabetes mellitus, back pain, and osteoarthritis.\(^4\) While evidence-based guidelines provide recommendations on how to provide effective weight management,\(^5\) \(^6\) excess weight and related complications remain under diagnosed and poorly treated.\(^7\) \(^8\)
Although evidence suggests that the vast majority of patients with overweight or obesity want their General Practitioner (GP) to bring up weight management during appointments, they seldom do. International experts agree that obesity stigma is a major barrier to seeking and receiving appropriate treatments for weight management. Past experiences of obesity stigma and weight-based discrimination may explain why so few people seek and receive appropriate treatment for obesity. Interestingly, the most important criterion GPs consider for initiating weight management conversations with a patient is if they have, or are at risk of developing, new or additional weight related health problems. This suggests that targeting weight related health status rather than obesity per se may overcome this barrier to initiating treatments in primary care.

The Edmonton Obesity Staging System (EOSS) is based on weight related health complications among individuals with overweight and obesity. A score of \( \geq 2 \) on the EOSS indicates the presence of clinically significant weight related complications requiring medical intervention. A brief diagnostic screening tool for predicting EOSS \( \geq 2 \) in patients with excess weight could provide GPs with a structured framework for further investigations to confirm a timely diagnosis in those who screen positive. It may also help GPs initiate a discussion about the health benefits of weight loss with patients, with or without mentioning obesity, resulting in improvements in their quality of care and health outcomes. Thus, we aimed to report the development and internal validation a simple screening tool (‘EOSS-2 Risk Tool’) to predict the presence of clinically significant weight related complications according to a diagnostic definition of EOSS \( \geq 2 \).

**Methods**

We present this paper according to the Journal’s formatting requirements and STROBE guidelines for reporting observational (cross-sectional) studies.
Study design, setting, and participants

We analysed cross-sectional data from the Australian Health Survey (AHS) 2011-13. For this study, we selected a subsample of participants aged 18 to 65 years who had measured anthropometry (n=7,518) with at least overweight (defined as a BMI of 25 kg/m² or higher) and/or central obesity (defined as a waist measurement of 102 cm and 88 cm or higher for all men and women, respectively).

Ethics approval and consent to participate

The Australian Bureau of Statistics was authorised to conduct the household interview components of the AHS Under the Census and Statistics Act 1905. The Australian Government Department of Health and Ageing’s Departmental Ethics Committee granted relevant ethical approvals (for the biomedical data collections in October 2011 and for the biomedical survey of the general population in February 2011). Written informed consent was obtained from participants separately for the in-home and pathology collection centre components.13

Patient and Public Involvement

No patient involved.

Variables

All survey questions are listed in the AHS User Guide.14

Diagnostic outcome

To create the diagnostic definition of EOSS stages, we used information from an extensive range of weight related health complications including chronic disease biomarkers (e.g.,
diabetes, high cholesterol, high triglycerides, chronic kidney disease, and abnormal liver enzymes), measured blood pressure, as well as self-reported long-term conditions, disability, psychological distress, health, and bodily pain. Specific criteria and thresholds for these variables were used to classify each participant into one of five EOSS categories based on our previous definition. Our analyses focused on differentiating the presence and absence of clinically significant weight related complications (EOSS 0-1 against EOSS 2-4).

**Candidate predictor variables**

To develop a simple tool that could easily be applied in general practice, like the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK), we considered self-reported predictor variables only. These included demographic variables (age, gender, and country of birth); medical history (history of depression or anxiety, family history of diabetes, hypertension, “high sugar in blood or urine”, and high cholesterol); lifestyle behaviours (smoking status, exercise, fruit and vegetable consumption); and functional health (self-rated health, bodily pain, and disability).

**Bias**

The focus of this study is the predictive accuracy of our screening test. This could be misstated if a large group with particularly poor (or good) predictive accuracy are excluded from the data set. We believe that this would be extremely unlikely.

**Sample size considerations**

The data set of 7,518 eligible individuals from the Australian Health Survey was split into a training data set and five test data sets. We randomly assigned about 40% (n=2,885) of data records to the training data set and about 12% (770) for each of the five test data sets. In the
training data set, we observed about 645 to be ‘lower risk’ (EOSS <2) and 2,240 to be ‘higher risk’ (EOSS ≥2) of clinically significant weight related complications. When considering up to 14 predictor variables, there was still a generous 46 ‘lower risk’ and 160 ‘higher risk’ individuals per predictor variable in the training data set. Each test data set was expected to contain about 172 ‘lower risk’ and 598 ‘higher risk’ individuals.

Statistical analysis

The diagnostic outcome of interest was presence of clinically significant weight related complications defined using EOSS stages ≥2. A total of 14 candidate predictor variables were considered (Table 1). We tested for statistical evidence of each variables distinguishing between the two EOSS groups (EOSS <2 vs EOSS ≥2) using Pearson’s χ² test. We considered that the performance of logistic regression would be affected by the probable size of the coefficients and the correlations between predictor variables as well as the number of events per variable. Thus, before model fitting, frequency counts were used to check for small categories in the categorical variables for exclusion.

Table 1. Candidate predictor variables from the Australian Health Survey (AHS) data 2011-13 by EOSS groups (<2 and ≥2)

| Variables | EOSS <2 (n=1678) | EOSS ≥2 (n=5840) | p-value |
|-----------|------------------|------------------|---------|
| Age       |                  |                  |         |
| 18-24 years | 178 (10.6%)    | 343 (5.9%)      | <0.001  |
| 25-34 years | 502 (29.9%)  | 940 (16.1%)     |         |
| 35-44 years | 482 (28.7%)  | 1337 (22.9%)    |         |
| 45-54 years | 352 (21.0%)  | 1603 (27.4%)    |         |
| 55-64 years | 164 (9.8%)   | 1617 (27.7%)    |         |
| Gender    |                  |                  | 0.011   |
| Males     | 889 (53.0%)  | 2889 (49.5%)    |         |
| Females   | 789 (47.0%)  | 2951 (50.5%)    |         |
| Variable                                           | Australia | Main English-speaking countries | Other | df | pvalue |
|---------------------------------------------------|-----------|---------------------------------|-------|----|--------|
| Country of birth                                  | 1226 (73.1%) | 4372 (74.9%)                    |       | 1  | 0.202  |
|                                                   | 193 (11.5%)  | 665 (11.4%)                     |       |    |        |
|                                                   | 259 (15.4%)  | 803 (13.7%)                     |       |    |        |
| Smoking status                                    |            |                                 |       |    |        |
| Non smoker                                        | 887 (52.9%)  | 2558 (43.8%)                    |       |    | <0.001 |
| Ex-smoker                                         | 453 (27.0%)  | 2008 (34.4%)                    |       |    |        |
| Current smoker                                    | 338 (20.1%)  | 1274 (21.8%)                    |       |    |        |
| Whether exercise met the recommended guidelines   |            |                                 |       |    | <0.001 |
| Yes                                               | 940 (56.0%)  | 2920 (50.0%)                    |       |    |        |
| No                                                | 735 (43.8%)  | 2913 (49.9%)                    |       |    |        |
| Unknown                                           | 3 (0.2%)     | 7 (0.1%)                        |       |    |        |
| Whether vegetable and fruit consumption met        |            |                                 |       |    | 0.766  |
| recommended guidelines                            |            |                                 |       |    |        |
| Yes                                               | 84 (5.0%)    | 303 (5.2%)                      |       |    |        |
| No                                                | 1594 (95.0%) | 5537 (94.8%)                    |       |    |        |
| Family history of diabetes                        |            |                                 |       |    | <0.001 |
| No                                                | 1276 (76.0%) | 3828 (65.5%)                    |       |    |        |
| Yes                                               | 383 (22.9%)  | 1884 (32.3%)                    |       |    |        |
| Unknown                                           | 19 (1.1%)    | 128 (2.2%)                      |       |    |        |
| Family history of high sugar in blood or urine    |            |                                 |       |    |        |
| No                                                | 1678 (100.0%) | 5455 (93.4%)                    |       |    |        |
| Yes                                               | 0 (0.0%*)    | 385 (6.6%)                      |       |    |        |
| History of depression or anxiety                  |            |                                 |       |    | <0.001 |
| No                                                | 1665 (99.2%) | 4574 (78.3%)                    |       |    |        |
| Yes                                               | 13 (0.8%)    | 1266 (21.7%)                    |       |    |        |
| Family history of hypertension                    |            |                                 |       |    |        |
| No                                                | 1678 (100.0%) | 4490 (76.9%)                    |       |    |        |
| Yes                                               | 0 (0.0%*)    | 1350 (23.1%)                    |       |    |        |
| Family history of high cholesterol levels         |            |                                 |       |    |        |
| No                                                | 1678 (100.0%) | 4734 (81.1%)                    |       |    |        |
| Yes                                               | 0 (0.0%*)    | 1106 (18.9%)                    |       |    |        |
| Self-assessed health                              |            |                                 |       |    |        |
| Excellent                                         | 492 (29.3%)  | 757 (13.0%)                     |       |    |        |
| Very good                                         | 740 (44.1%)  | 2028 (34.7%)                    |       |    |        |
| Good                                              | 394 (23.5%)  | 2008 (34.4%)                    |       |    |        |
| Fair                                              | 52 (3.1%)    | 772 (13.2%)                     |       |    |        |
| Disability status                                                                 | % | <0.001 |
|----------------------------------------------------------------------------------|---|--------|
| Has no limitation or specific restriction or disability or long term condition    | 1432 (85.4%) | 3859 (66.0%) |
| Has mild core/school/employment activity limitation                              | 32 (1.9%) | 652 (11.2%) |
| Has moderate core activity limitation                                              | 0 (0.0%) | 478 (8.2%) |
| Has severe core activity limitation                                               | 4 (0.2%) | 273 (4.7%) |
| Has profound core activity limitation                                             | 210 (12.5%) | 578 (9.9%) |

| Bodily pain in the last 4 weeks                                                   | % |        |
|----------------------------------------------------------------------------------|---|--------|
| None                                                                             | 779 (46.4%) | 1366 (23.4%) |
| Very mild/ mild                                                                  | 897 (53.5%) | 2385 (40.8%) |
| Moderate                                                                         | 1676 (0.0%) | 1462 (25.1%) |
| Severe                                                                           | 0 (0.0%) | 487 (8.3%) |
| Very severe                                                                       | 0 (0.0%) | 130 (2.2%) |
| Unknown                                                                          | 2 (0.1%) | 10 (0.2%) |

*Structural zeros were either due to the definitional variables (variables or levels of variables that were used to define EOSS ≥2) or those variables that had significant correlation to EOSS ≥2.

**Model development**

We used logistic regression analysis to assess diagnostic models from the training data and apply the results in the test data sets. In addition, structural zeros resulting from definitional variables that were used in the diagnostic definition of EOSS ≥2 and variables with obvious correlation were pragmatically included in the screening tool, bypassing the candidate diagnostic modelling. Definitional variables include one or more levels of variables including poor level of self-assessed health, moderate to severe levels of bodily pain, and moderate to profound levels of disability.

For the less obvious candidate variables, we used univariate logistic regression analysis to investigate the predictive ability of each variable independently. Statistics used to assess predictive ability included statistical significance, goodness of fit, and Area under the Receiver Operating Characteristic (AROC) curve. We retained only those variables that were judged to
be clinically relevant and displaying at least some indication of predictive ability for the candidate diagnostic modelling.

Next, we built different candidate diagnostic models for predicting EOSS $\geq 2$ using a combination of clinical judgement and statistical performance. Each model comprised of five to six variables that were retained for multivariate logistic modelling. For each candidate diagnostic model, we used a multivariate logistic regression analysis where variables that were without obvious clinical importance and had a non-significant effect on the model were sequentially eliminated in a backward stepwise manner. The final step of the candidate diagnostic models consisted of only those variables that were statistically significant ($p < 0.05$).

**Model selection and scoring system**

We compared different models for predicting EOSS $\geq 2$. Of these, we chose the model which was consistently observed to have the best discrimination using AROC and the Hosmer–Lemeshow (HL) $\chi^2$ statistic (HL $\chi^2$ statistic $< 20$ represents good calibration with a $p$-value $\geq 0.01$) across the five test data sets.$^{17}$ Once the list of predictors was finalised, we then fitted the model on the whole combined data set of 7,518 participants. A simple scoring system for the EOSS-2 Risk Tool was obtained by dividing the regression ($\beta$) coefficient for each variable in the final model by the lowest $\beta$ coefficient, then multiplying by two and rounding to the nearest integer.$^{18}$ A ROC curve was fitted to the final model and we used the co-ordinates of the curve to determine the cut-off score with the maximum sensitivity, specificity, and Positive Predictive Value (PPV).

**Model validation**

The test data sets were used to evaluate the performance and transportability of the model to individuals who were not involved in the development. It is generally recommended to have
multiple test data sets, so as to test the model on varying case mix, with each containing 200 or more events. The final model was validated on each of the five test data sets. We assessed performance of the final model on each of the five test data sets using sensitivity, specificity, and PPV statistics (Table 2). All analyses were conducted using Statistical Package for the Social Sciences (SPSS) version 26 (IBM Corp, Armonk, NY, USA).

Table 2. Performance of the final model in the training and test datasets

| Type of dataset† | AROC (95% CI) | HL χ² statistic | HL χ² p-value | Sensitivity | Specificity | PPV |
|------------------|---------------|----------------|---------------|-------------|-------------|-----|
| Training dataset (n=1,408) | 0.71 (0.68, 0.73) | 3.87 | 0.868 | 64% | 63% | 64% |
| Test dataset 1 (n=478) | 0.67 (0.62, 0.71) | 6.00 | 0.647 | 60% | 59% | 60% |
| Test dataset 2 (n=467) | 0.70 (0.66, 0.75) | 6.09 | 0.637 | 63% | 67% | 63% |
| Test dataset 3 (n=474) | 0.70 (0.65, 0.74) | 3.56 | 0.895 | 62% | 63% | 62% |
| Test dataset 4 (n=481) | 0.69 (0.64, 0.73) | 3.26 | 0.917 | 62% | 64% | 62% |
| Test dataset 5 (n=507) | 0.66 (0.60, 0.70) | 5.31 | 0.724 | 60% | 58% | 60% |

†Final model – Age, self-assessed health, and history of depression or anxiety.
AROC - Area under the Receiver Operating Characteristic curve; HL - Hosmer–Lemeshow; PPV – Positive Predictive Value.
‡The reduced number in each dataset is due to removal of observations that had structural zeros and variables with significant correlation to EOSS ≥2 from candidate diagnostic modelling.

Results

Of the 7,518 participants, 1,678 (22%) were classified into the EOSS <2 group and 5,840 (78%) were classified into the EOSS ≥2 group. Participants in the EOSS ≥2 tended to be older, current or ex-smokers, with poorer self-rated health and did not meet the recommended exercise guidelines compared to the EOSS <2 group (Table 1). The definitional variables along with
variables (family history of diabetes, hypertension, high sugar in blood urine, and high cholesterol) identified as having obvious correlation to EOSS ≥2 were automatically included in our final screening tool without having to be considered in the modelling.

Model development

In the univariate logistic regression analysis, we identified nine out of eleven variables to be independent predictors of EOSS ≥2 which were subsequently retained for the candidate diagnostic modelling. Of the nine variables in the multivariate logistic regression analysis, age, self-assessed health, and history of depression or anxiety were found to be consistently significant at the final step of the training and test data sets. The AROC for the final model in the training data set was 0.71 (95% CI 0.68-0.73). Using a cut-off score of ≥7, the sensitivity, specificity and PPV for identifying EOSS ≥2 in the training data set was 64%, 63%, and 64%, respectively (Table 2). The β coefficients for the final model and the scores allocated to each risk factor category were then computed (Table 3). To create the final paper-based version of the EOSS-2 Risk Tool, we included the three definitional variables and variables with significant correlation to EOSS ≥2 (assigned a maximum score of 25 each) along with the three risk factors in the final diagnostic model.11

| Predictors | β coefficient | p-value | Points allocated |
|------------|---------------|---------|------------------|
| Age groups |               |         |                  |
| 18-24 years| Reference     |         | 0                |
| 25-34 years| 0.889         | 0.599   | 2                |
| 35-44 years| 1.268         | 0.291   | 3                |
| 45-54 years| 2.034         | 0.002   | 5                |
| 55-64 years| 2.637         | <0.001  | 6                |

Table 3. Beta coefficients from the multiple logistic regression final model predicting EOSS ≥2, and points allocated to each component of the EOSS-2 score
### Self-assessed health

| Health          | Reference | Value  | p-value |
|-----------------|-----------|--------|---------|
| Excellent       | Reference | 0      |         |
| Very good       | 1.492     | 0.006  | 3       |
| Good            | 2.144     | <0.001 | 5       |
| Fair            | 3.731     | <0.001 | 8       |

### History of depression or anxiety

| Depression or Anxiety | Reference | Value  | p-value |
|-----------------------|-----------|--------|---------|
| No                    | Reference | 0      |         |
| Yes                   | 21.727    | <0.001 | 10*     |

*Scores for EOSS-2 risk screening tool was obtained by dividing the regression (β) coefficient for each variable in the final model by the lowest β coefficient, then multiplying by 2 and rounding to the nearest integer.

*For practical reasons, positive history of depression or anxiety was scored 10.

†In addition to the three predictors in the final model, definitional and correlational variables (family history of diabetes, hypertension, high sugar in blood/urine, high cholesterol, self-reported bodily pain, and disability) automatically predicting EOSS ≥2 were also added to the EOSS-2 tool and were assigned a maximum score of 25.

---

**Model validation**

Upon validation of the final model on the five test data sets, we found that the EOSS-2 Risk Tool had similar discriminative ability in predicting EOSS ≥2 with an AROC ranging between 0.66 and 0.70 and was well calibrated as compared to the training data set (Table 2). In assessing the effectiveness of the EOSS-2 risk tool on the combined data set of 7,518 participants, we found that the risk tool correctly identified 89% (n =4,483) of those at ‘extremely high risk’ and 67% (n =839) of those at ‘very high risk’ as having EOSS ≥2. Almost 42% (n =518) of those screened to be high risk were actually EOSS ≥2 (Table 4). Based on the PPV%, we used specific thresholds for the EOSS-2 Risk Tool scores to define ‘high risk’ (<7 points), ‘very high risk’ (7-24 points), and ‘extremely high risk’ (≥25 points) of having a diagnosis of clinically significant weight related complications according to EOSS ≥2.

---

**Table 4. Cross tabulation of EOSS assessment versus model outcome in the combined dataset (n=7,518)**

| EOSS by assessment | EOSS by model outcome |
|--------------------|-----------------------|
Discussion

We have developed a simple, safe, and accurate screening tool (‘EOSS-2 Risk Tool’) to predict the presence of unknown clinically significant weight related complications according to a diagnostic definition of EOSS stages 2-4, based on nine self-reported risk factors relevant to the Australian population. A score of 25 or more was assigned to six out of nine risk factors to automatically predict having an ‘extremely high risk’ of meeting diagnostic criteria for EOSS ≥2 with 100% accuracy, as expected (Table 4). For EOSS scores less than 25 assigned to the remaining three risk factors, the results of our validation work selected a threshold of 7 points to discriminate between ‘high risk’ (<7 points) and ‘very high risk’ (7-24 points) groups for predicting diagnostic criteria for EOSS ≥2, with excellent performance characteristics (PPV values of 60% and 86%, respectively).

The EOSS-2 Risk Tool may provide GPs with a new screening tool for conducting further investigations in their patients who screen positive to confirm a timely diagnosis of clinically significant weight related complications indicating medical intervention. Guidelines released by the Royal Australian College of General Practitioners (‘Red Book’) recommend similar screening tools, such as the AUSDRISK for assessing risk of diabetes, and the Cardio Vascular Disease (CVD) risk calculator for assessing absolute CVD risk, both in ‘high risk’ patients, typically aged 40 and 45 years or more, respectively. The AUSDRISK risk factors include gender, age, ethnicity/country of birth, family history of diabetes/high blood sugar, medication for high blood pressure, lifestyle behaviours smoking, fruit/vegetables, exercise), and waist circumference. The CVD risk tool, developed by the National Vascular Disease...
Prevention Alliance, is based on the Framingham Risk Equation. The risk factors include gender, age, systolic blood pressure, smoking status, total cholesterol level, high-density lipoprotein-cholesterol level, diabetes status, and left ventricular hypertrophy (by electrocardiography).

The EOSS-2 Risk Tool is unique because it considers functional health status and quality of life in screening for risk of meeting diagnostic criteria for EOSS ≥2. It may present GPs with an opportunity to set new clinical targets in their patients based on EOSS stage (e.g., from EOSS 2 to 1) with appropriate intervention. This would ensure that the focus of weight management is holistic, and complications based. The AROC of 0.71 for the EOSS-2 Risk Tool is slightly smaller than those reported for the AUSDRISK (AROC of 0.78) and Framingham Risk Equation (C-Statistic of 0.74 for men and 0.80 for women).

The EOSS-2 Risk Tool may also help GPs initiate a discussion about the health benefits of weight loss with their patients opportunistically during appointments. Results of the ACTION-IO study found that there was very strong agreement among both patients and health care professionals about the health benefits of modest weight loss of 5-10% in patients with excess weight. Furthermore, patients reported that their most important weight loss goal was to reduce health risks associated with excess weight. Similarly, GPs reported that a specific personal medical event (e.g., CVD) or diagnosis (e.g., diabetes, liver disease, sleep apnoea) was the most important motivation to lose weight in patients. This suggests that screening for clinically significant weight related complications may help GPs activate weight management discussions with, and treatments for, their patients. We recently published the first evidence of a nationwide pilot study supporting the clinical usefulness of the EOSS-2 Risk Tool for activating weight management discussions in general practice, although further research is required to assess its scalability in Australia’s health care system. Despite their variable application in Australian general practice, both the AUSDRISK and CVD risk tools are
considered clinically useful for patient engagement and education, as well as assessment and management of risk followed by appropriate diagnostic tests. The EOSS-2 Risk Tool could also be used by other health care professionals involved in multidisciplinary clinical obesity services in both public hospitals and private settings such as nurses, dietitians, clinical psychologists, exercise physiologists, and physiotherapists.

We acknowledge study limitations and potential risks of bias associated with the data source and methods used, additional to those previously reported. As there is no universal definition of EOSS criteria, the performance of the tool based on other diagnostic definitions of EOSS ≥2 needs to be established. We recently published a rapid review of relevant studies and highlighted the need for developing standardized tools for clinical settings based on a consistent set of criteria with standardized cut-offs for classifying people into EOSS categories. As with the AUSDRISK and CVD risk tools, the EOSS-2 Risk Tool was developed and validated in a population-based sample and may not be relevant to patients in primary care settings. The false positive results may result in unnecessary follow-up tests on some patients. But even with these errors it is still an improvement on the current circumstance where the GP would need to test every patient with at least overweight to confirm an EOSS diagnosis. Furthermore and despite financial incentives, the implementation of these types of screening tools into routine general practice remains challenging.

Conclusions

The new EOSS-2 Risk Tool is a simple, safe, and accurate screening tool for detecting the presence of unknown clinically significant weight related complications, based on our diagnostic definition of EOSS ≥2, in a ‘high risk’ subsample of the Australian population. Research to determine the scalability of the EOSS-2 Risk Tool for improving weight management approaches in general practice is warranted.
**Data Availability Statement**

Access to the data set used in this study is subject to the requirements of the Australian Bureau of Statistics: [https://www.abs.gov.au/websitedbs/D3310114.nsf/home/MicrodataDownload](https://www.abs.gov.au/websitedbs/D3310114.nsf/home/MicrodataDownload)

**Ethics Statement**

The Australian Bureau of Statistics was authorised to conduct the household interview components of the AHS Under the Census and Statistics Act 1905. The Australian Government Department of Health and Ageing’s Departmental Ethics Committee granted relevant ethical approvals (for the biomedical data collections in October 2011 and for the biomedical survey of the general population in February 2011). Written informed consent was obtained from participants separately for the in-home and pathology collection centre components.

**Funding Statement**

This pilot work was supported by grants from iNova Pharmaceuticals (Australia) Pty Ltd (https://inovapharma.com/), in partnership with the National Association of Clinical Obesity Services Incorporated (https://www.nacos.org.au/) and Western Sydney University (https://www.westernsydney.edu.au/) (P00026836: EA, JRJ, PPF, and KP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interest Statement**

EA was the Founding President, and now serves as the Secretary, of NACOS. He has received honoraria from Novo Nordisk for speaking and participating at meetings. He has received unrestricted research funding from Novo Nordisk and iNova on behalf of NACOS. JRJ
received payment for his role as the project manager through casual employment contracts at Western Sydney University. SH has received honoraria from Novo Nordisk, iNova, Sanofi, Lilly, Boehringer Ingelheim, Servier, MSD and Astra Zeneca for seminar presentations. She has served on advisory boards for Lilly, iNova, Pfizer and Novo Nordisk. She has received research funding from Novo Nordisk. She is the current the President of NACOS. PPF and KP declared that no competing interest exists.

Contributorship Statement

EA conceived the study, contributed to data interpretation, and led the manuscript drafting. JRJ and PF led the data analysis, interpretation of data outputs, and contributed to drafting the manuscript. EA, JRJ, and PF were accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SH, KP, KW, and PD contributed to drafting and revising the manuscript for important intellectual content. All the authors read and agreed to submit the published version of the manuscript.

 References

1. Wolfenden L, Ezzati M, Larijani B, et al. The challenge for global health systems in preventing and managing obesity. *Obes Rev* 2019;20 Suppl 2:185-93. doi: 10.1111/obr.12872 [published Online First: 2019/07/19]

2. AIHW. Overweight and obesity: an interactive insight. Cat. no: PHE 251. Web report. https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity-an-interactive-insight/contents/what-is-overweight-and-obesity. 2021

3. Atlantis E, Fahey P, Williams K, et al. Comparing the predictive ability of the Edmonton Obesity Staging System with the body mass index for use of health services and
pharmacotherapies in Australian adults: A nationally representative cross-sectional study. *Clin Obes* 2020;10(4):e12368. doi: 10.1111/cob.12368 [published Online First: 2020/05/19]

4. Australian Institute of Health and Welfare 2017. Impact of overweight and obesity as a risk factor for chronic conditions: Australian Burden of Disease Study. Australian Burden of Disease Study series no.11. Cat. no. BOD 12. BOD. Canberra: AIHW.

5. Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines. *Obes Rev* 2019;20(9):1218-30. doi: 10.1111/obr.12889 [published Online First: 2019/07/10]

6. RACGP. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 9th edn. East Melbourne, Vic: . 2016

7. Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: Misalignment between perception, reality and actions in obesity. *Diabetes, Obesity and Metabolism* 2019;21(8):1914-24. doi: 10.1111/dom.13752

8. Nordmo M, Danielsen YS, Nordmo M. The challenge of keeping it off, a descriptive systematic review of high-quality, follow-up studies of obesity treatments. *Obes Rev* 2020;21(1):e12949. doi: 10.1111/obr.12949 [published Online First: 2019/11/02]

9. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. *Nature Medicine* 2020;26(4):485-97. doi: 10.1038/s41591-020-0803-x

10. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. *Int J Obes (Lond)* 2009;33(3):289-95. doi: 10.1038/ijo.2009.2 [published Online First: 2009/02/04]

11. Atlantis E, John JR, Fahey PP, et al. Clinical usefulness of brief screening tool for activating weight management discussions in primary cARE (AWARE): A nationwide mixed
methods pilot study. *PLoS One* 2021;16(10):e0259220. doi: 10.1371/journal.pone.0259220 [published Online First: 2021/10/29]

12. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of Clinical Epidemiology* 2008;61(4):344-49. doi: [https://doi.org/10.1016/j.jclinepi.2007.11.008](https://doi.org/10.1016/j.jclinepi.2007.11.008)

13. Australian Bureau of Statistics. Australian Health Survey: Users' Guide, 2011-13 2013.

14. Australian Bureau of Statistics. 4363.0.55.001 - Australian Health Survey: Users' Guide, 2011-13

15. Chen L, Magliano DJ, Balkau B, et al. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. *Med J Aust* 2010;192(4):197-202. doi: 10.5694/j.1326-5377.2010.tb03507.x [published Online First: 2010/02/23]

16. Courvoisier DS, Combescure C, Agoritsas T, et al. Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure. *Journal of clinical epidemiology* 2011;64(9):993-1000.

17. Hosmer DW, Hjort NL. Goodness-of-fit processes for logistic regression: simulation results. *Statistics in medicine* 2002;21(18):2723-38.

18. Sullivan LM, Massaro JM, D'Agostino Sr RB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Statistics in medicine* 2004;23(10):1631-60.

19. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. *Statistics in medicine* 2016;35(2):214-26.
20. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1 Pt 2):293-8.

21. Albarqouni L, Doust JA, Magliano D, et al. External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study. *Med J Aust* 2019;210(4):161-67. doi: 10.5694/mja2.12061 [published Online First: 2019/01/19]

22. Wong KC, Brown AM, Li SC. AUSDRISK - application in general practice. *Aust Fam Physician* 2011;40(7):524-6. [published Online First: 2011/07/12]

23. Chiang J, Furler J, Boyle D, et al. Electronic clinical decision support tool for the evaluation of cardiovascular risk in general practice: A pilot study. *Aust Fam Physician* 2017;46(10):764-68. [published Online First: 2017/10/19]

24. Gupta R, Stocks NP, Broadbent J. Cardiovascular risk assessment in Australian general practice. *Australian Family Physician* 2009;38(5):364-68.

25. National Association of Clinical Obesity Services. National Framework for Clinical Obesity Services. First Edition, NACOS 2020, VIC 3926 Australia.

https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkupdated24022020.pdf

https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkAppendix20012020.pdf, 2019

26. Atlantis E, Kormas N, Samaras K, et al. Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus. *Clin Obes* 2018;8(3):203-10. doi: 10.1111/cob.12249 [published Online First: 2018/04/24]

27. Atlantis E, Sahebolamri M, Cheema BS, et al. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies. *Obes Rev* 2020;21(11):e13120. doi: 10.1111/obr.13120 [published Online First: 2020/08/20]
28. Stocks N, Allan J, Frank O, et al. Improving attendance for cardiovascular risk assessment in Australian general practice: an RCT of a monetary incentive for patients. *Bmc Fam Pract* 2012;13 doi: Artn 54

10.1186/1471-2296-13-54

29. Torley D, Zwar N, Comino EJ, et al. GPs' views of absolute cardiovascular risk and its role in primary prevention. *Aust Fam Physician* 2005;34(6):503-4, 07. [published Online First: 2005/06/03]
Development and internal validation of the Edmonton Obesity Staging System-2 Risk screening Tool (EOSS-2 Risk Tool) for weight related health complications: a case-control study in a representative sample of Australian adults with overweight and obesity

| Journal: | BMJ Open |
| --- | --- |
| Manuscript ID | bmjopen-2022-061251.R1 |
| Article Type: | Original research |
| Date Submitted by the Author: | 26-May-2022 |

| Complete List of Authors: | Atlantis, Evan; Western Sydney University; The University of Sydney John, James Rufus; Western Sydney University Hocking, SL; University of Sydney, Charles Perkins Centre Peters, Kath; Western Sydney University Williams, Kathryn; The University of Sydney Dugdale, Paul; ANU, College of Medicine Biology and Environment Fahey, P; Western Sydney, School of Science and Health |

| Primary Subject Heading: | General practice / Family practice |
| Secondary Subject Heading: | Diagnostics, General practice / Family practice |
| Keywords: | GENERAL MEDICINE (see Internal Medicine), Diabetes & endocrinology < INTERNAL MEDICINE, PRIMARY CARE, PREVENTIVE MEDICINE |
I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (“BMJ”) its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge (“APC”) for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which Creative Commons licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author’s Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.
Development and internal validation of the Edmonton Obesity Staging System-2 Risk screening Tool (EOSS-2 Risk Tool) for weight related health complications: a case-control study in a representative sample of Australian adults with overweight and obesity

Evan Atlantis1,2*; James Rufus John3,4; Samantha Hocking5,6; Kath Peters1; Kathryn Williams7,8; Paul Dugdale9; Paul Fahey1

1School of Health Sciences, Western Sydney University, Penrith, New South Wales, Australia
2Discipline of Medicine, Nepean Clinical School, Faculty of Medicine and Health, The University of Sydney, Nepean, New South Wales, Australia
3Discipline of Psychiatry and Mental Health, School of Clinical Medicine, University of New South Wales, Sydney, New South Wales, Australia
4Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia
5The Boden Collaboration for Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, The University of Sydney, Camperdown, New South Wales, Australia
6Metabolism & Obesity Services, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
7Charles Perkins Centre – Nepean, The University of Sydney, New South Wales, Australia
8Nepean Blue Mountains Family Metabolic Heath Service, The Nepean Blue Mountains Local Health District, Nepean, New South Wales, Australia
9College of Health and Medicine, Australian National University, Canberra, Australian Capital Territory, Australia

*Corresponding author:
Email: E.Atlantis@westernsydney.edu.au
Short running title Development and internal validation of the EOSS-2 Risk Tool.

Keywords Weight Related Complications; Diagnostic Techniques and Procedures; Mass Screening; Overweight

Abstract

Objective

Excess weight and related health complications remain under diagnosed and poorly treated in general practice. We aimed to develop and validate a brief screening tool for determining the presence of unknown clinically significant weight related health complications for potential application in general practice.

Design

We considered 14 self-reported candidate predictors of clinically significant weight related health complications according to the Edmonton Obesity Staging System (EOSS score of ≥2) and developed models using multivariate logistic regression across training and test data sets. The final model was chosen based on the Area under the Receiver Operating Characteristic (AROC) curve and the Hosmer–Lemeshow (HL) statistic; and validated using sensitivity, specificity, and positive predictive value.

Setting and participants

We analysed cross-sectional data from the Australian Health Survey 2011-13 sample aged between 18 and 65 years (n=7,518) with at least overweight and obesity.

Results

An EOSS ≥2 classification was present in 78% of the sample. Of 14 candidate risk factors, six (family history of diabetes, hypertension, high sugar in blood/urine, high cholesterol, and self-reported bodily pain and disability) were automatically included based on definitional or obvious correlational criteria. Three variables were retained in the final multivariate model
(age, self-assessed health, and history of depression/anxiety). The EOSS-2 Risk Tool (index test) classified 89% of those at ‘extremely high risk’ (≥25 points), 67% of those at ‘very high risk’ (7-24 points), and 42% of those at ‘high risk’ (<7 points) of meeting diagnostic criteria for EOSS ≥2 (reference).

**Conclusion**

The EOSS-2 Risk Tool is a simple, safe, and accurate screening tool for diagnostic criteria for clinically significant weight related complications for potential application in general practice. Research to determine the feasibility and applicability of the EOSS-2 Risk Tool for improving weight management approaches in general practice is warranted.

**Strengths and limitations of this study**

- The EOSS-2 Risk Tool was developed and validated in an Australian sample of community-based ‘high risk’ individuals for potential application in general practice.
- The EOSS-2 Risk Tool efficiently detects the presence of unknown clinically significant weight related complications according to the widely used Edmonton Obesity Staging System.
- Research to determine the feasibility and applicability of the EOSS-2 Risk Tool for improving weight management approaches in specific general practice settings is warranted.

**Introduction**

Overweight and obesity is a major public health issue challenging global health systems.¹ It affects a quarter of all young people (aged 2-17 years) and two-thirds of all adults in Australia.² We recently estimated that millions of Australians have weight related health complications (complex and/or chronic conditions) associated with increased avoidable health service use and
hospitalizations. The most common weight related health problems include cancer, stroke, heart disease, kidney disease, dementia, diabetes mellitus, back pain, and osteoarthritis. While evidence-based guidelines provide recommendations on how to provide effective weight management, excess weight and related complications remain under diagnosed and poorly treated.

Although evidence suggests that the vast majority of patients with overweight and obesity want their General Practitioner (GP) to bring up weight management during appointments, they seldom do. International experts agree that obesity stigma is a major barrier to seeking and receiving appropriate treatments for weight management. Past experiences of obesity stigma and weight-based discrimination may explain why so few people seek and receive appropriate treatment for obesity. Interestingly, the most important criterion GPs consider for initiating weight management conversations with a patient is if they have, or are at risk of developing, new or additional weight related health problems. This suggests that targeting weight related health status rather than obesity per se may overcome this barrier to initiating treatments in primary care.

The Edmonton Obesity Staging System (EOSS) is based on weight related health complications among individuals with overweight and obesity. A score of ≥2 on the EOSS indicates the presence of clinically significant weight related complications requiring medical intervention. A brief diagnostic screening tool for predicting EOSS ≥2 in patients with excess weight could provide GPs with a structured framework for further investigations to confirm a timely diagnosis in those who screen positive. It may also help GPs initiate a discussion about the health benefits of weight loss with patients, with or without mentioning obesity, resulting in improvements in their quality of care and health outcomes. Thus, we aimed to report the development and internal validation a simple screening tool (‘EOSS-2 Risk Tool’) to estimate the risk of clinically significant weight related complications according to a diagnostic
definition of EOSS $\geq 2$.3

Methods

We present this paper according to the Journal’s formatting requirements and STROBE guidelines for reporting observational (cross-sectional) studies.12

Study design, setting, and participants

We analysed cross-sectional data from the Australian Health Survey (AHS) 2011-13 and partially corrected for at State, section of State, sex, and age group levels in the weighting process. It is the largest survey with biochemical and physical measurements ever conducted in Australia. For this study, we selected a subsample of participants aged 18 to 65 years who had measured anthropometry ($n=7,518$) with at least overweight (defined as a BMI of 25 kg/m$^2$ or higher) and/or central obesity (defined as a waist measurement of 102 cm and 88 cm or higher for all men and women, respectively).

Ethics approval and consent to participate

The Australian Bureau of Statistics was authorised to conduct the household interview components of the AHS Under the Census and Statistics Act 1905. The Australian Government Department of Health and Ageing’s Departmental Ethics Committee granted relevant ethical approvals (for the biomedical data collections in October 2011 and for the biomedical survey of the general population in February 2011). Written informed consent was obtained from participants separately for the in-home and pathology collection centre components.13

Patient and public involvement

No patient involved.
Variables

All survey questions are listed in the AHS User Guide.\textsuperscript{13}

Diagnostic outcome

To create the diagnostic definition of EOSS stages, we used information from an extensive range of weight related health complications including chronic disease biomarkers (e.g., diabetes, high cholesterol, high triglycerides, chronic kidney disease, and abnormal liver enzymes), measured blood pressure, as well as self-reported long-term conditions, disability, psychological distress, health, and bodily pain. Specific criteria and thresholds for these variables were used to classify each participant into one of five EOSS categories based on our previous definition (online supplemental material).\textsuperscript{3} Each category reflects the most severe EOSS stage according to weight related complications for that individual. Given the absence of internationally consistent criteria for assigning weight related health impairments into EOSS categories,\textsuperscript{14} we chose this reference standard which has been validated in an Australian sample of community-based ‘high risk’ individuals.\textsuperscript{3} Our analyses focused on differentiating the presence and absence of clinically significant weight related complications (EOSS 0-1 against EOSS 2-4).

Candidate predictor variables

To develop a simple tool that could easily be applied in general practice, like the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK),\textsuperscript{15} we considered self-reported predictor variables only. These included demographic variables (age, gender, and country of birth); medical history (history of depression or anxiety, family history of diabetes, hypertension, “high sugar in blood or urine”, and high cholesterol); lifestyle behaviours (smoking status,
exercise, fruit and vegetable consumption); and functional health (self-rated health, bodily pain, and disability).

**Bias**

The AHS achieved a high response rate of 85% defined by fully/adequate responding households, after sample loss. A focus of this study is the predictive accuracy of our screening test, which could be misrepresented if a large group with particularly poor (or good) predictive accuracy were excluded from the data set. We believe that this would be extremely unlikely. Missing data was not considered since we used specific selection criteria for our training and test data sets.

**Sample size considerations**

The data set of 7,518 eligible individuals from the AHS was split into a training data set and five test data sets. We randomly assigned about 40% \((n=2,885)\) of data records to the training data set and about 12% \((770)\) for each of the five test data sets. In the training data set, we observed about 645 to be ‘lower risk’ \((\text{EOSS} < 2)\) and 2,240 to be ‘higher risk’ \((\text{EOSS} \geq 2)\) of clinically significant weight related complications. When considering up to 14 predictor variables, there was still a generous 46 ‘lower risk’ and 160 ‘higher risk’ individuals per predictor variable in the training data set. Each test data set was expected to contain about 172 ‘lower risk’ and 598 ‘higher risk’ individuals.

**Statistical analysis**

The diagnostic outcome of interest was presence of clinically significant weight related complications defined using EOSS stages \(\geq 2\). A total of 14 candidate predictor variables were considered (Table 1). We tested for statistical evidence of each variable distinguishing between
the two EOSS groups (EOSS <2 vs EOSS ≥2) using Pearson’s $\chi^2$ test. We considered that the
performance of logistic regression would be affected by the probable size of the coefficients
and the correlations between predictor variables as well as the number of events per variable.\textsuperscript{16}
Thus, before model fitting, frequency counts were used to check for small categories in the
categorical variables for exclusion.

Table 1. Candidate predictor variables from the Australian Health Survey data 2011-13
by EOSS groups (<2 and ≥2)

| Variables                        | EOSS <2 (n=1,678) | EOSS ≥2 (n=5,840) | p-value |
|----------------------------------|-------------------|-------------------|---------|
| **Age**                          |                   |                   |         |
| 18-24 years                      | 178 (10.6%)       | 343 (5.9%)        | <0.001  |
| 25-34 years                      | 502 (29.9%)       | 940 (16.1%)       |         |
| 35-44 years                      | 482 (28.7%)       | 1337 (22.9%)      |         |
| 45-54 years                      | 352 (21.0%)       | 1603 (27.4%)      |         |
| 55-64 years                      | 164 (9.8%)        | 1617 (27.7%)      |         |
| **Gender**                       |                   |                   | 0.011   |
| Males                            | 889 (53.0%)       | 2889 (49.5%)      |         |
| Females                          | 789 (47.0%)       | 2951 (50.5%)      |         |
| **Country of birth**             |                   |                   | 0.202   |
| Australia                        | 1226 (73.1%)      | 4372 (74.9%)      |         |
| Main English-speaking countries  | 193 (11.5%)       | 665 (11.4%)       |         |
| Other                            | 259 (15.4%)       | 803 (13.7%)       |         |
| **Smoking status**               |                   |                   | <0.001  |
| Non smoker                       | 887 (52.9%)       | 2558 (43.8%)      |         |
| Ex-smoker                        | 453 (27.0%)       | 2008 (34.4%)      |         |
| Current smoker                   | 338 (20.1%)       | 1274 (21.8%)      |         |
| **Whether exercise met the recommended guidelines** | | | <0.001 |
| Yes                              | 940 (56.0%)       | 2920 (50.0%)      |         |
| No                               | 735 (43.8%)       | 2913 (49.9%)      |         |
| Unknown                          | 3 (0.2%)          | 7 (0.1%)          |         |
| **Whether vegetable and fruit consumption met recommended guidelines** | | | 0.766 |
| Yes                              | 84 (5.0%)         | 303 (5.2%)        |         |
|                                | No                  | Yes                 |
|--------------------------------|---------------------|---------------------|
| **Family history of diabetes** |                     |                     |
| No                             | 1594 (95.0%)        | 5537 (94.8%)        |
| Yes                            | 1276 (76.0%)        | 3828 (65.5%)        |
| Unknown                        | 383 (22.9%)         | 1884 (32.3%)        |
| **Family history of high sugar in blood or urine** | | | <0.001 |
| No                             | 1678 (100.0%)       | 5455 (93.4%)        |
| Yes                            | 0 (0.0%)*           | 385 (6.6%)          |
| **History of depression or anxiety** |                     |                     |
| No                             | 1665 (99.2%)        | 4574 (78.3%)        |
| Yes                            | 13 (0.8%)           | 1266 (21.7%)        |
| **Family history of hypertension** |                     |                     |
| No                             | 1678 (100.0%)       | 4490 (76.9%)        |
| Yes                            | 0 (0.0%)*           | 1350 (23.1%)        |
| **Family history of high cholesterol levels** | | | |
| No                             | 1678 (100.0%)       | 4734 (81.1%)        |
| Yes                            | 0 (0.0%)*           | 1106 (18.9%)        |
| **Self-assessed health**       |                     |                     |
| Excellent                      | 492 (29.3%)         | 757 (13.0%)         |
| Very good                      | 740 (44.1%)         | 2028 (34.7%)        |
| Good                           | 394 (23.5%)         | 2008 (34.4%)        |
| Fair                           | 52 (3.1%)           | 772 (13.2%)         |
| Poor                           | 0 (0.0%)*           | 275 (4.7%)          |
| **Disability status**          |                     |                     |
| Has no limitation or specific restriction or disability or long term condition | 1432 (85.4%) | 3859 (66.0%) |
| Has mild core/school/employment activity limitation | 32 (1.9%) | 652 (11.2%) |
| Has moderate core activity limitation | 0 (0.0%) | 478 (8.2%) |
| Has severe core activity limitation | 4 (0.2%) | 273 (4.7%) |
| Has profound core activity limitation | 210 (12.5%) | 578 (9.9%) |
| **Bodily pain in the last 4 weeks** |                     |                     |
| None                           | 779 (46.4%)         | 1366 (23.4%)        |
| Very mild/ mild                | 897 (53.5%)         | 2385 (40.8%)        |
| Moderate                       | 1676 (0.0%*)        | 1462 (25.1%)        |
| Severe                         | 0 (0.0%*)           | 487 (8.3%)          |
| Very severe                    | 0 (0.0%*)           | 130 (2.2%)          |
| Unknown                        | 2 (0.1%)            | 10 (0.2%)           |
**Structural zeros were either due to the definitional variables (variables or levels of variables that were used to define EOSS ≥2) or those variables that had significant correlation to EOSS ≥2.**

**Model development**

We used logistic regression analysis to assess diagnostic models from the training data and apply the results in the test data sets. In addition, structural zeros resulting from definitional variables that were used in the diagnostic definition of EOSS ≥2 and variables with obvious correlation were pragmatically included in the screening tool, bypassing the logistic diagnostic modelling. The self-reported conditions include one or more levels of variables including poor level of self-assessed health, moderate to severe levels of bodily pain, and moderate to profound levels of disability.

For the other candidate variables, we used univariate logistic regression analysis to investigate their ability to discriminate the presence or absence of EOSS ≥2 based on diagnostic criteria (reference) versus the EOSS index test (EOSS-2 Risk screening Tool) independently. Statistics used to assess predictive ability included statistical significance, goodness of fit, and Area under the Receiver Operating Characteristic (AROC) curve. We retained only those variables that were judged to be clinically relevant and displaying at least some indication of predictive ability for the candidate diagnostic modelling.

Next, we built different candidate diagnostic models for predicting EOSS ≥2 using a combination of clinical judgement and statistical performance. Each model comprised of five to six variables that were retained for multivariate logistic modelling. For each candidate diagnostic model, we used a multivariate logistic regression analysis where variables that were without obvious clinical importance and had a non-significant effect on the model were sequentially eliminated in a backward stepwise manner. The final step of the candidate diagnostic models consisted of only those variables that were statistically significant (p <0.05).
Model selection and scoring system

We compared different models for predicting EOSS ≥2. Of these, we chose the model which was consistently observed to have the best discrimination using AROC and the Hosmer–Lemeshow (HL) $\chi^2$ statistic (HL $\chi^2$ statistic <20 represents good calibration with a p-value ≥0.01) across the five test data sets.\textsuperscript{17} Once the list of predictors was finalised, we then fitted the model on the whole combined data set of 7,518 participants. To simplify the scoring system for the EOSS-2 Risk Tool, integer scores were obtained by dividing the regression ($\beta$) coefficient for each variable in the final model by the lowest $\beta$ coefficient, then multiplying by two and rounding to the nearest integer.\textsuperscript{18} We capped the maximum score at 10 which we believed was sufficient to convey the substantially increased risk of weight related complications for those groups (five times larger than the smallest odds ratio). A ROC curve was fitted to the simplified scoring system and we used the co-ordinates of the curve to determine the cut-off score with the maximum sensitivity, specificity, and Positive Predictive Value (PPV).

Model validation

The test data sets were used to evaluate the performance and transportability of the model to individuals who were not involved in the development. It is generally recommended to have multiple test data sets, so as to test the model on varying case mix, with each containing 200 or more events.\textsuperscript{19} The final model was validated on each of the five test data sets. We assessed performance of the final model on each of the five test data sets using sensitivity, specificity, and PPV statistics (Table 2). All analyses were conducted using Statistical Package for the Social Sciences (SPSS) version 26 (IBM Corp, Armonk, NY, USA).
Table 2. Performance of the final model† in the training and test datasets

| Type of dataset‡ | AROC (95% CI) | HL χ² statistic | HL χ² p-value | Sensitivity | Specificity | PPV |
|------------------|---------------|----------------|--------------|-------------|-------------|-----|
| Training dataset (n=1,408) | 0.71 (0.68, 0.73) | 3.87 | 0.868 | 64% | 63% | 64% |
| Test dataset 1 (n=478) | 0.67 (0.62, 0.71) | 6.00 | 0.647 | 60% | 59% | 60% |
| Test dataset 2 (n=467) | 0.70 (0.66, 0.75) | 6.09 | 0.637 | 63% | 67% | 63% |
| Test dataset 3 (n=474) | 0.70 (0.65, 0.74) | 3.56 | 0.895 | 62% | 63% | 62% |
| Test dataset 4 (n=481) | 0.69 (0.64, 0.73) | 3.26 | 0.917 | 62% | 64% | 62% |
| Test dataset 5 (n=507) | 0.66 (0.60, 0.70) | 5.31 | 0.724 | 60% | 58% | 60% |

†Final model – Age, self-assessed health, and history of depression or anxiety.

AROC - Area under the Receiver Operating Characteristic curve; HL - Hosmer–Lemeshow; PPV – Positive Predictive Value.

‡The reduced number in each dataset is due to removal of observations that had structural zeros and variables with significant correlation to EOSS ≥2 from candidate diagnostic modelling.

Results

Of the 7,518 participants, 1,678 (22%) were classified into the EOSS <2 group and 5,840 (78%) were classified into the EOSS ≥2 group. Participants in the EOSS ≥2 tended to be older, current, or ex-smokers, with poorer self-rated health and did not meet the recommended exercise guidelines compared to the EOSS <2 group (Table 1). The definitional variables along with variables (family history of diabetes, hypertension, high sugar in blood urine, and high cholesterol) identified as having obvious correlation to EOSS ≥2 were automatically included in our final screening tool without having to be considered in the modelling.

Model development
In the univariate logistic regression analysis, we identified nine out of eleven variables to be independent predictors of EOSS ≥2 which were subsequently retained for the candidate diagnostic modelling. Of the nine variables in the multivariate logistic regression analysis, age, self-assessed health, and history of depression or anxiety were found to be consistently significant at the final step of the training and test data sets. The AROC for the final model in the training data set was 0.71 (95% CI 0.68-0.73). Using a cut-off score of ≥7, the sensitivity, specificity and PPV for identifying EOSS ≥2 in the training data set was 64%, 63%, and 64%, respectively (Table 2). The β coefficients for the final model and the scores allocated to each risk factor category were then computed (Table 3). To create the final paper-based version of the EOSS-2 Risk Tool, we included the three definitional variables and variables with significant correlation to EOSS ≥2 (assigned a maximum score of 25 each) along with the three risk factors in the final diagnostic model.11

Table 3. Beta coefficients from the multiple logistic regression final model predicting EOSS ≥2 and points allocated to each component of the EOSS-2 score

| Predictors† | β coefficient | p-value | Points allocated‡ |
|-------------|---------------|---------|-------------------|
| **Age groups** |               |         |                   |
| 18-24 years | Reference     |         | 0                 |
| 25-34 years | 0.889         | 0.599   | 2                 |
| 35-44 years | 1.268         | 0.291   | 3                 |
| 45-54 years | 2.034         | 0.002   | 5                 |
| 55-64 years | 2.637         | <0.001  | 6                 |
| **Self-assessed health** | |         |                   |
| Excellent   | Reference     |         | 0                 |
| Very good   | 1.492         | 0.006   | 3                 |
| Good        | 2.144         | <0.001  | 5                 |
| Fair        | 3.731         | <0.001  | 8                 |
| **History of depression or anxiety** | |         |                   |
| No          | Reference     |         | 0                 |
| Yes         | 21.727        | <0.001  | 10*               |
†Scores for EOSS-2 Risk screening Tool was obtained by dividing the regression (β) coefficient for each variable in the final model by the lowest β coefficient, then multiplying by 2 and rounding to the nearest integer.

*For practical reasons, positive history of depression or anxiety was scored 10.

‡In addition to the three predictors in the final model, definitional and correlational variables (family history of diabetes, hypertension, high sugar in blood/urine, high cholesterol, self-reported bodily pain, and disability) automatically predicting EOSS ≥2 were also added to the EOSS-2 Risk Tool and were assigned a maximum score of 25.

Model validation

Upon validation of the final model on the five test data sets, we found that the EOSS-2 Risk Tool had similar discriminative ability in predicting EOSS ≥2 with an AROC ranging between 0.66 and 0.70 and was well calibrated as compared to the training data set (Table 2). In assessing the effectiveness of the EOSS-2 risk tool on the combined data set of 7,518 participants, we found that 89% (n=4,483) of those classified as ‘extremely high risk’ did indeed have EOSS ≥2. Thus, ‘extremely high risk’ is an appropriate descriptor for a PPV of 89%, ‘very high risk’ is an appropriate descriptor for a PPV of 67% (n=839), and ‘high risk’ is appropriate descriptor for a PPV of 42% (n=518) (Table 4). Based on these PPVs, we used specific thresholds for the EOSS-2 Risk Tool scores to define ‘high risk’ (<7 points), ‘very high risk’ (7-24 points), and ‘extremely high risk’ (≥25 points) of having a diagnosis of clinically significant weight related complications according to EOSS ≥2.

Table 4. Cross tabulation of EOSS based on diagnostic criteria (reference) versus the EOSS index test (EOSS-2 Risk screening Tool) in the combined dataset (n=7,518)

| EOSS (reference) | EOSS index test |  |
|------------------|-----------------|---|
|                  | High risk (<7)  | Very high risk (7-24) | Extremely high risk (≥25) | Total |
| EOSS ≥2         | 518 (41.5%)     | 839 (67.0%)           | 4,483 (89.4%)              | 5,840 (77.7%) |
| EOSS <2         | 731 (58.5%)     | 414 (33.0%)           | 533 (10.6%)                | 1,678 (22.3%) |
Discussion

We have developed a simple, safe, and accurate screening tool (‘EOSS-2 Risk Tool’) to predict the presence of unknown clinically significant weight related complications according to a diagnostic definition of EOSS stages 2-4,\(^3\) based on nine self-reported risk factors\(^{11}\) relevant to the Australian population. A score of 25 or more was assigned to six out of nine risk factors to automatically predict having an ‘extremely high risk’ of meeting diagnostic criteria for EOSS \(\geq 2\) with 100% accuracy, as expected (Table 4). For EOSS scores less than 25 assigned to the remaining three risk factors, the results of our validation work selected a threshold of 7 points to discriminate between ‘high risk’ (<7 points) and ‘very high risk’ (7-24 points) groups for predicting diagnostic criteria for EOSS \(\geq 2\), with excellent performance characteristics. We recommend that GPs use the EOSS-2 Risk Tool as a screening tool in all patients with suspected overweight and obesity, regardless of their lowest risk score (‘high risk’), to warrant further investigations and confirm the presence and severity of weight related complications and diagnostic criteria for EOSS staging. This is because all three risk categories reflect increasing degrees of risk for weight related complications according to our diagnostic criteria for EOSS stages 2-4.

The EOSS-2 Risk Tool may provide GPs with a new screening tool for conducting further investigations in their patients who screen positive to confirm a timely diagnosis of clinically significant weight related complications indicating medical intervention. Guidelines released by the Royal Australian College of General Practitioners (‘Red Book’) recommend similar screening tools, such as the AUSDRISK\(^{15}\) for assessing risk of diabetes, and the Cardio Vascular Disease (CVD) risk calculator for assessing absolute CVD risk,\(^6\) both in ‘high risk’ patients, typically aged 40 and 45 years or more, respectively. The AUSDRISK risk factors
include gender, age, ethnicity/country of birth, family history of diabetes/high blood sugar, medication for high blood pressure, lifestyle behaviours smoking, fruit/vegetables, exercise), and waist circumference. The CVD risk tool, developed by the National Vascular Disease Prevention Alliance, is based on the Framingham Risk Equation. The risk factors include gender, age, systolic blood pressure, smoking status, total cholesterol level, high-density lipoprotein-cholesterol level, diabetes status, and left ventricular hypertrophy (by electrocardiography).

The EOSS-2 Risk Tool is unique because it considers functional health status and quality of life in screening for risk of meeting diagnostic criteria for EOSS ≥2. It may present GPs with an opportunity to set new clinical targets in their patients based on diagnostic criteria for EOSS stages (e.g., from EOSS 2 to 1) with appropriate intervention. This would ensure that the focus of weight management is holistic, and complications based. The AROC of 0.71 for the EOSS-2 Risk Tool is slightly smaller than those reported for the AUSDRISK (AROC of 0.78) and Framingham Risk Equation (C-Statistic of 0.74 for men and 0.80 for women).

The EOSS-2 Risk Tool may also help GPs initiate a discussion about the health benefits of weight loss with their patients opportunistically during appointments. Results of the ACTION-IO study found that there was very strong agreement among both patients and health care professionals about the health benefits of modest weight loss of 5-10% in patient with excess weight. Furthermore, patients reported that their most important weight loss goal was to reduce health risks associated with excess weight. Similarly, GPs reported that a specific personal medical event (e.g., CVD) or diagnosis (e.g., diabetes, liver disease, sleep apnoea) was the most important motivation to lose weight in patients. This suggests that screening for clinically significant weight related complications may help GPs activate weight management discussions with, and treatments for, their patients. We recently published the first evidence of a nationwide pilot study supporting the clinical usefulness of the EOSS-2 Risk Tool (including
a paper-based version) for activating weight management discussions in general practice, although further research is required to assess its scalability in Australia’s health care system.\textsuperscript{11} Despite their variable application in Australian general practice, both the AUSDRISK and CVD risk tools are considered clinically useful for patient engagement and education, as well as assessment and management of risk followed by appropriate diagnostic tests.\textsuperscript{22-24} The EOSS-2 Risk Tool could also be used by other health care professionals involved in multidisciplinary clinical obesity services in both public hospitals and private settings such as nurses, dietitians, clinical psychologists, exercise physiologists, and physiotherapists.\textsuperscript{25 26}

We acknowledge study limitations and potential risks of bias associated with the data source and methods used, additional to those previously reported.\textsuperscript{3} As there is no universal definition of EOSS criteria, the performance of the tool based on other diagnostic definitions of EOSS $\geq 2$ needs to be established. We recently published a rapid review of relevant studies and highlighted the need for developing standardized tools for clinical settings based on a consistent set of criteria with standardized cut-offs for classifying people into EOSS categories.\textsuperscript{14} As with the AUSDRISK\textsuperscript{15} and CVD risk\textsuperscript{20} tools, the EOSS-2 Risk Tool was developed and validated in a population-based sample and may not be relevant to patients in primary care settings. Furthermore and despite financial incentives,\textsuperscript{22 27} the implementation of these types of screening tools into routine general practice remains challenging.\textsuperscript{22 28}

Conclusions

The new EOSS-2 Risk Tool is a simple, safe, and accurate screening tool for detecting the presence of unknown clinically significant weight related complications, based on our diagnostic definition of EOSS $\geq 2$, in a subsample of the Australian population with overweight and obesity. Research to determine the scalability of the EOSS-2 Risk Tool for improving weight management approaches in general practice is warranted.
Data Availability Statement

Access to the data set used in this study is subject to the requirements of the Australian Bureau of Statistics: https://www.abs.gov.au/websitedbs/D3310114.nsf/home/MicrodataDownload

Ethics Statement

The Australian Bureau of Statistics was authorised to conduct the household interview components of the AHS Under the Census and Statistics Act 1905. The Australian Government Department of Health and Ageing’s Departmental Ethics Committee granted relevant ethical approvals (for the biomedical data collections in October 2011 and for the biomedical survey of the general population in February 2011). Written informed consent was obtained from participants separately for the in-home and pathology collection centre components.

Funding Statement

This pilot work was supported by grants from iNova Pharmaceuticals (Australia) Pty Ltd (https://inovapharma.com/), in partnership with the National Association of Clinical Obesity Services Incorporated (https://www.nacos.org.au/) and Western Sydney University (https://www.westernsydney.edu.au/) (P00026836: EA, JRJ, PPF, and KP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interest Statement

EA was the Founding President, and now serves as the Secretary, of NACOS. He has received honoraria from Novo Nordisk for speaking and participating at meetings. He has received unrestricted research funding from Novo Nordisk and iNova on behalf of NACOS. JRJ received payment for his role as the project manager through casual employment contracts at Western Sydney University. SH has received honoraria from Novo Nordisk, iNova, Sanofi, Lilly, Boehringer Ingelheim, Servier, MSD and Astra Zeneca for seminar presentations. She has served on advisory boards for Lilly, iNova, Pfizer and Novo Nordisk. She has received research funding from Novo Nordisk. She is the current the President of NACOS. PPF and KP declared that no competing interest exists.

References

1. Wolfenden L, Ezzati M, Larijani B, et al. The challenge for global health systems in preventing and managing obesity. *Obes Rev* 2019;20 Suppl 2:185-93. doi: 10.1111/obr.12872 [published Online First: 2019/07/19]

2. AIHW. Overweight and obesity: an interactive insight. Cat. no: PHE 251. Web report. [https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity-an-interactive-insight/contents/what-is-overweight-and-obesity](https://www.aihw.gov.au/reports/overweight-obesity/overweight-and-obesity-an-interactive-insight/contents/what-is-overweight-and-obesity) 2021

3. Atlantis E, Fahey P, Williams K, et al. Comparing the predictive ability of the Edmonton Obesity Staging System with the body mass index for use of health services and pharmacotherapies in Australian adults: A nationally representative cross-sectional study. *Clin Obes* 2020;10(4):e12368. doi: 10.1111/cob.12368 [published Online First: 2020/05/19]
4. Australian Institute of Health and Welfare 2017. Impact of overweight and obesity as a risk factor for chronic conditions: Australian Burden of Disease Study. Australian Burden of Disease Study series no.11. Cat. no. BOD 12. BOD. Canberra: AIHW.

5. Semlitsch T, Stigler FL, Jeitler K, et al. Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines. *Obes Rev* 2019;20(9):1218-30. doi: 10.1111/obr.12889 [published Online First: 2019/07/10]

6. RACGP. The Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice. 9th edn. East Melbourne, Vic: . 2016

7. Caterson ID, Alfadda AA, Auerbach P, et al. Gaps to bridge: Misalignment between perception, reality and actions in obesity. *Diabetes, Obesity and Metabolism* 2019;21(8):1914-24. doi: 10.1111/dom.13752

8. Nordmo M, Danielsen YS, Nordmo M. The challenge of keeping it off, a descriptive systematic review of high-quality, follow-up studies of obesity treatments. *Obes Rev* 2020;21(1):e12949. doi: 10.1111/obr.12949 [published Online First: 2019/11/02]

9. Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. *Nature Medicine* 2020;26(4):485-97. doi: 10.1038/s41591-020-0803-x

10. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. *Int J Obes (Lond)* 2009;33(3):289-95. doi: 10.1038/ijo.2009.2 [published Online First: 2009/02/04]

11. Atlantis E, John JR, Fahey PP, et al. Clinical usefulness of brief screening tool for activating weight management discussions in primary cARE (AWARE): A nationwide mixed methods pilot study. *PLoS One* 2021;16(10):e0259220. doi: 10.1371/journal.pone.0259220 [published Online First: 2021/10/29]
12. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of Clinical Epidemiology* 2008;61(4):344-49. doi: https://doi.org/10.1016/j.jclinepi.2007.11.008

13. Australian Bureau of Statistics. 4363.0.55.001 - Australian Health Survey: Users' Guide, 2011-13

14. Atlantis E, Sahebolamri M, Cheema BS, et al. Usefulness of the Edmonton Obesity Staging System for stratifying the presence and severity of weight-related health problems in clinical and community settings: A rapid review of observational studies. *Obes Rev* 2020;21(11):e13120. doi: 10.1111/obr.13120 [published Online First: 2020/08/20]

15. Chen L, Magliano DJ, Balkau B, et al. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. *Med J Aust* 2010;192(4):197-202. doi: 10.5694/j.1326-5377.2010.tb03507.x [published Online First: 2010/02/23]

16. Courvoisier DS, Combescure C, Agoritsas T, et al. Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure. *Journal of clinical epidemiology* 2011;64(9):993-1000.

17. Hosmer DW, Hjort NL. Goodness-of-fit processes for logistic regression: simulation results. *Statistics in medicine* 2002;21(18):2723-38.

18. Sullivan LM, Massaro JM, D'Agostino Sr RB. Presentation of multivariate data for clinical use: The Framingham Study risk score functions. *Statistics in medicine* 2004;23(10):1631-60.

19. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for the external validation of a multivariable prognostic model: a resampling study. *Statistics in medicine* 2016;35(2):214-26.
20. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. *Am Heart J* 1991;121(1 Pt 2):293-8.

21. Albarqouni L, Doust JA, Magliano D, et al. External validation and comparison of four cardiovascular risk prediction models with data from the Australian Diabetes, Obesity and Lifestyle study. *Med J Aust* 2019;210(4):161-67. doi: 10.5694/mja2.12061 [published Online First: 2019/01/19]

22. Wong KC, Brown AM, Li SC. AUSDRISK - application in general practice. *Aust Fam Physician* 2011;40(7):524-6. [published Online First: 2011/07/12]

23. Chiang J, Furler J, Boyle D, et al. Electronic clinical decision support tool for the evaluation of cardiovascular risk in general practice: A pilot study. *Aust Fam Physician* 2017;46(10):764-68. [published Online First: 2017/10/19]

24. Gupta R, Stocks NP, Broadbent J. Cardiovascular risk assessment in Australian general practice. *Australian Family Physician* 2009;38(5):364-68.

25. National Association of Clinical Obesity Services. National Framework for Clinical Obesity Services. First Edition, NACOS 2020, VIC 3926 Australia. [https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkupdated24022020.pdf](https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkupdated24022020.pdf) [https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkAppendix20012020.pdf](https://www.nacos.org.au/base/wp-content/uploads/NACOSFrameworkAppendix20012020.pdf), 2019

26. Atlantis E, Kormas N, Samaras K, et al. Clinical Obesity Services in Public Hospitals in Australia: a position statement based on expert consensus. *Clin Obes* 2018;8(3):203-10. doi: 10.1111/cob.12249 [published Online First: 2018/04/24]

27. Stocks N, Allan J, Frank O, et al. Improving attendance for cardiovascular risk assessment in Australian general practice: an RCT of a monetary incentive for patients. *Bmc Fam Pract* 2012;13 doi: Artn 54

10.1186/1471-2296-13-54
28. Torley D, Zwar N, Comino EJ, et al. GPs' views of absolute cardiovascular risk and its role in primary prevention. *Aust Fam Physician* 2005;34(6):503-4, 07. [published Online First: 2005/06/03]

**Author Statement**

EA conceived the study, contributed to data interpretation, and led the manuscript drafting. JRJ and PF led the data analysis, interpretation of data outputs, and contributed to drafting the manuscript. EA, JRJ, and PF were accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. SH, KP, KW, and PD contributed to drafting and revising the manuscript for important intellectual content. All the authors read and agreed to submit the published version of the manuscript.
Supplementary Material: Specific criteria and thresholds for variables used to classify each participant into one of the five EOSS categories

| Criteria                                      | EOSS categories and criteria |
|-----------------------------------------------|------------------------------|
| Fasting plasma glucose (FPG) diabetes status (mmol/L) | 0 | 1 | 2 | 3 | 4 |
| <6.1                                          | x                           |    |    |    |    |
| 6.1 - <7.0                                    | x                           |    |    |    |    |
| ≥7.0                                          | x                           |    |    |    |    |
| HbA1c diabetes status (%)                     | 0 | 1 | 2 | 3 | 4 |
| <6.0                                          | x                           |    |    |    |    |
| 6.0 - <6.5                                    | x                           |    |    |    |    |
| ≥6.5                                          | x                           |    |    |    |    |
| Systolic Blood Pressure (mmHg)                | 0 | 1 | 2 | 3 | 4 |
| <130                                          | x                           |    |    |    |    |
| ≥130 - 139.9                                  | x                           |    |    |    |    |
| ≥140                                          | x                           |    |    |    |    |
| Diastolic Blood Pressure (mmHg)               | 0 | 1 | 2 | 3 | 4 |
| <85                                           | x                           |    |    |    |    |
| ≥85 - 89.9                                    | x                           |    |    |    |    |
| ≥90                                           | x                           |    |    |    |    |
| Total Cholesterol (mmol/L)                    | 0 | 1 | 2 | 3 | 4 |
| <5.0                                          | x                           |    |    |    |    |
| 5.0 - <6.0                                    | x                           |    |    |    |    |
| ≥6.0                                          | x                           |    |    |    |    |
| Fasting triglycerides (mmol/L)                | 0 | 1 | 2 | 3 | 4 |
| <1.5                                          | x                           |    |    |    |    |
| 1.5 - <2.5                                    | x                           |    |    |    |    |
| ≥2.5                                          | x                           |    |    |    |    |
| Fasting LDL cholesterol - ranged (mmol/L)     | 0 | 1 | 2 | 3 | 4 |
| <2.5                                          | x                           |    |    |    |    |
| 2.5 - <4.0                                    | x                           |    |    |    |    |
| ≥4.0                                          | x                           |    |    |    |    |
| HDL cholesterol - ranged (mmol/L)             | 0 | 1 | 2 | 3 | 4 |
| ≥1.5                                          | x                           |    |    |    |    |
| 1.0 - <1.5                                    | x                           |    |    |    |    |
| <1.0                                          | x                           |    |    |    |    |
| Alanine aminotransferase (ALT) - categories (U/L) MALES | 0 | 1 | 2 | 3 | 4 |
| <30                                           | x                           |    |    |    |    |
| 30 - <40                                      | x                           |    |    |    |    |
| ≥40                                           | x                           |    |    |    |    |
| Alanine aminotransferase (ALT) - categories (U/L) FEMALES | 0 | 1 | 2 | 3 | 4 |
| <25                                           | x                           |    |    |    |    |
| 25 - <35                                      | x                           |    |    |    |    |
| Parameter                                                                 | Male (U/L) | Female (U/L) |
|--------------------------------------------------------------------------|------------|--------------|
| Gamma glutamyl transferase (GGT)                                         |            |              |
| ≥35                                                                      | x          |              |
| ≤30                                                                      |            |              |
| 30 - <50                                                                 | x          |              |
| ≥50                                                                      | x          |              |
| Chronic Kidney Disease (CKD) stages                                      |            |              |
| No indicators of CKD                                                     | x          |              |
| Stage 1                                                                  |            |              |
| Stage 2                                                                  |            |              |
| Stage 3a + 3b                                                            |            |              |
| Stages 4 - 5                                                             |            | x            |
| Self-reported weight related chronic diseases                            | x          |              |
| Other endocrine nutritional metabolic diseases                            |            | x            |
| Diabetes mellitus - Type 2                                               |            | x            |
| Diabetes mellitus - Type 1                                               |            | x            |
| Diabetes mellitus - Type unknown                                         |            | x            |
| High sugar levels in blood/urine                                         | x          |              |
| High cholesterol                                                         |            |              |
| Gestational diabetes                                                     | x          |              |
| Anxiety related problems                                                 | x          |              |
| Depression                                                               |            |              |
| Other diseases of veins lymphatic vessels                                |            | x            |
| Diseases of arteries arterioles & capillaries                            |            | x            |
| Angina                                                                   |            |              |
| Oedema                                                                   |            | x            |
| Other signs symptoms involving circulatory system                        | x          |              |
| Tachycardia                                                              | x          |              |
| Other diseases of circulatory system                                     | x          |              |
| Other heart diseases                                                     | x          |              |
| Other Ischaemic heart diseases                                           | x          |              |
| Heart attack                                                             |            | x            |
| Heart failure                                                            |            |              |
| Cardiac murmurs and cardiac sounds                                      | x          |              |
| Hypertensive disease                                                     |            | x            |
| Other cerebrovascular diseases                                           |            | x            |
| Stroke (including after effects of stroke)                               |            | x            |
| Varicose veins                                                           | x          |              |
| Haemorrhoids                                                             | x          |              |
| Sciatica                                                                 | x          |              |
| Arthritis - Osteoarthritis                                               |            | x            |
| Condition                                                                 | Status |
|---------------------------------------------------------------------------|--------|
| Gout                                                                      | x      |
| Back pain/problems not elsewhere classified                               | x      |
| Kidney disease                                                            | x      |
| Bronchitis                                                                | x      |
| Emphysema                                                                 | x      |
| Asthma                                                                    | x      |
| Other diseases of the oesophagus, stomach & duodenum                      | x      |
| All other diseases of the digestive system                                 | x      |
| Diseases of the oesophagus                                                 | x      |
| Stomach/duodenal/gastrointestinal ulcer                                   | x      |
| Hernia                                                                    | x      |
| Gallstones                                                                 | x      |
| Other arthropathies                                                        | x      |
| Other soft tissue disorders                                                | x      |
| Disc disorders                                                             | x      |
| Other diseases musculoskeletal system & connective tissue                 | x      |
| Rheumatism                                                                | x      |
| Diseases of female pelvic organs & genital tract                           | x      |
| Diseases of male genital organs                                           | x      |
| Incontinence: urine                                                       | x      |
| Sprains & Strains & Tears of ligament, muscle or tendon                   | x      |
| Injury joint, knee not elsewhere classified                                | x      |
| Fluid retention (non circulatory)                                          | x      |
| **Kessler Psychological Distress Scale-10 (K10) score categories**         |        |
| 10                                                                        | x      |
| >10 - 15                                                                  | x      |
| 16 - 21                                                                   | x      |
| 22 - 29                                                                   | x      |
| 30 - 50                                                                   | x      |
| **Self-assessed health (SF-12 or other)**                                 |        |
| 1. Excellent                                                              | x      |
| 2. Very good                                                              | x      |
| 3. Good                                                                   | x      |
| 4. Fair                                                                   | x      |
| 5. Poor                                                                   | x      |
| **Disability status**                                                     |        |
| 1. Has profound core activity limitation                                  | x      |
| 2. Has severe core activity limitation                                    | x      |
| 3. Has moderate core activity limitation                                   | x      |
| 4. Has mild core activity limitation                                       | x      |
| 5. Has a schooling/employment restriction only                            | x      |
| 6. Has no limitation or specific restriction                              | x      |
| 7. Has no disability or long-term health condition                        | x      |
| **Bodily pain experienced in the last four weeks**                        |        |
|   |   |
|---|---|
| 1. None | x |
| 2. Very mild | x |
| 3. Mild | x |
| 4. Moderate | x |
| 5. Severe | x |
| 6. Very severe | x |